Advanced

Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines.

Svensson, Åke LU ; Möller, Halvor LU ; Björkner, Bert LU ; Bruze, Magnus LU ; Leden, Ido; Theander, Jan; Ohlsson, Kjell and Linder, Carina LU (2002) In BMC Dermatology 2(1).
Abstract
Objective



To study the clinical and biochemical effects of a low starting dose for gold therapy in rheumatoid arthritis patients with a contact allergy to gold.

Methods



Serum cytokines were assayed before and 24 h after the first injection of gold sodium thiomalate (GSTM).

Results



Contact allergy to gold was found in 4 of 19 patients. Compared to gold-negative patients (starting dose: 10 mg GSTM), there was a larger increase in serum TNFalpha (p < 0.05), sTNF-R1 (NS), and IL-1 ra (p < 0.05) in gold-allergic patients.

Conclusions



Cytokines are released in blood by GSTM in RA patients with gold allergy. To minimize the risk of acute... (More)
Objective



To study the clinical and biochemical effects of a low starting dose for gold therapy in rheumatoid arthritis patients with a contact allergy to gold.

Methods



Serum cytokines were assayed before and 24 h after the first injection of gold sodium thiomalate (GSTM).

Results



Contact allergy to gold was found in 4 of 19 patients. Compared to gold-negative patients (starting dose: 10 mg GSTM), there was a larger increase in serum TNFalpha (p < 0.05), sTNF-R1 (NS), and IL-1 ra (p < 0.05) in gold-allergic patients.

Conclusions



Cytokines are released in blood by GSTM in RA patients with gold allergy. To minimize the risk of acute adverse reactions the starting dose of GSTM should be lowered to 5 mg. Alternatively, patients should be patch-tested before gold therapy; in test-positive cases, 5 mg is recommended as the first dose. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
BMC Dermatology
volume
2
issue
1
publisher
BioMed Central
external identifiers
  • scopus:2942535835
ISSN
1471-5945
DOI
10.1186/1471-5945-2-2
language
English
LU publication?
yes
id
00134d2a-c9c4-4b8a-9e1f-d141cb2794e2 (old id 115560)
alternative location
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11860615&dopt=Abstract
date added to LUP
2007-07-19 15:39:02
date last changed
2017-01-01 07:15:37
@article{00134d2a-c9c4-4b8a-9e1f-d141cb2794e2,
  abstract     = {Objective<br/><br>
<br/><br>
To study the clinical and biochemical effects of a low starting dose for gold therapy in rheumatoid arthritis patients with a contact allergy to gold.<br/><br>
Methods<br/><br>
<br/><br>
Serum cytokines were assayed before and 24 h after the first injection of gold sodium thiomalate (GSTM).<br/><br>
Results<br/><br>
<br/><br>
Contact allergy to gold was found in 4 of 19 patients. Compared to gold-negative patients (starting dose: 10 mg GSTM), there was a larger increase in serum TNFalpha (p &lt; 0.05), sTNF-R1 (NS), and IL-1 ra (p &lt; 0.05) in gold-allergic patients.<br/><br>
Conclusions<br/><br>
<br/><br>
Cytokines are released in blood by GSTM in RA patients with gold allergy. To minimize the risk of acute adverse reactions the starting dose of GSTM should be lowered to 5 mg. Alternatively, patients should be patch-tested before gold therapy; in test-positive cases, 5 mg is recommended as the first dose.},
  author       = {Svensson, Åke and Möller, Halvor and Björkner, Bert and Bruze, Magnus and Leden, Ido and Theander, Jan and Ohlsson, Kjell and Linder, Carina},
  issn         = {1471-5945},
  language     = {eng},
  number       = {1},
  publisher    = {BioMed Central},
  series       = {BMC Dermatology},
  title        = {Rheumatoid arthritis, gold therapy, contact allergy and blood cytokines.},
  url          = {http://dx.doi.org/10.1186/1471-5945-2-2},
  volume       = {2},
  year         = {2002},
}